<DOC>
	<DOCNO>NCT02294058</DOCNO>
	<brief_summary>The purpose study determine whether RPC1063 effective treatment relapse multiple sclerosis ( RMS ) .</brief_summary>
	<brief_title>Phase 3 Study RPC1063 Relapsing MS</brief_title>
	<detailed_description>The purpose study learn effect safety experimental medication RPC1063 take mouth treatment Relapsing Multiple Sclerosis ( RMS ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>Multiple sclerosis diagnose revised 2010 McDonald criterion EDSS score 0 5.0 baseline â€¢ Primary progressive multiple sclerosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>MS</keyword>
	<keyword>RMS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
</DOC>